Guggenheim Initiates Coverage On Solid Biosciences with Buy Rating, Announces Price Target of $26

Guggenheim analyst Debjit Chattopadhyay has initiated coverage on Solid Biosciences (NASDAQ: SLDB) with a Buy rating. The firm has set a price target of $26 for the company's stock.